Retention Rate of Acalabrutinib in a Non-interventional Setting

Retention Rate of Acalabrutinib in a Non-interventional Setting

Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.

This observational study will prospectively assess acalabrutinib therapy retention of CLL patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. Furthermore, therapy adherence, treatment efficacy, overall survival, and QoL to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. Finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, QoL, and psychological segmentation.

Inclusion Criteria:

• Age ≥ 18 years
• Diagnosis of CLL
• Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives
• Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy.
• Provision of signed informed consent form

Exclusion Criteria:

• Current or planned participation in an interventional clinical trial
• Contraindications to treatment with acalabrutinib according to the current SmPC
• Pregnancy or breast feeding
• Disease progression on prior BTKi therapy
• Start of acalabrutinib therapy more than 28 days prior to enrolment